AbbVie submits new drug application to USFDA for Tavapadon for Parkinsons disease
North Chicago: AbbVie has announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tavapadon, a novel selective dopamine D1/D5 receptor…
September 28, 2025